2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1231

Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis
Abstract Number: 2543

Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
Abstract Number: 1144

Impact of Decision-Making Role Preferences in the Efficacy of a Multimedia Patient Education Tool for Patients with Common Rheumatologic Conditions
Abstract Number: 1766

Impact of Depression on SLE Flares
Abstract Number: 2077

Impact of Diabetes, Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Statin Use on Presentation and Outcomes in Patients with Giant Cell Arteritis
Abstract Number: 2730

Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting
Abstract Number: 1164

Impact of E-Learning on Knowledge, Self-Efficacy and Exercise Behaviours of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial
Abstract Number: 1163

Impact of E-Learning on Perceived Social Role Participation of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial
Abstract Number: 1906

Impact of Environmental Factors and Inflammation on Alterations of the Total Peripheral T-Cell Compartment in Granulomatosis with Polyangiitis
Abstract Number: 2220

Impact of Fibromyalgia on DAS28 in Patients with Rheumatoid Arthritis
Abstract Number: 232

Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Abstract Number: 720

Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World
Abstract Number: 2047

Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus
Abstract Number: 30

Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis
Abstract Number: 2551

Impact of Multmorbidity on Disability and Disease Activity over Time in Patients with RA Taking Biologics: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].